Physician profile
Lee Steven Cohen
NPI 1174669683
$690,173.18
in general payments reported to CMS, 2019-2025
24 companies · $213K in 2025
The $213K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $77K · 2021: $65K · 2022: $43K · 2023: $65K · 2024: $133K · 2025: $213K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $302K · Consulting Fee: $37K · Honoraria: $36K · Travel and Lodging: $17K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,000 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $301,867.50 |
| Consulting Fee | $37,121.20 |
| Honoraria | $36,276.00 |
| Travel and Lodging | $17,016.40 |
| Food and Beverage | $13,139.17 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,000.00 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279,964.71 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $129,536.59 | 2024-2025 | Cobenfy |
| Allergan, INC. | $92,396.73 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $54,440.15 | 2019-2021 | |
| Axsome Therapeutics, INC. | $46,246.55 | 2024-2025 | Auvelity, Sunosi |
| Corium, LLC | $34,146.10 | 2022-2025 | Azstarys, Azstarys |
| Sunovion Pharmaceuticals INC. | $24,920.44 | 2019-2021 | |
| Tris Pharma INC | $9,190.30 | 2019-2023 | Quillivant, Quillichew Er, Dyanavel Xr |
| Neurocrine Biosciences, INC. | $8,230.36 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $6,151.99 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,556.91 | 2020-2025 | Caplyta |
| Neos Therapeutics, Lp | $752.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $143.95 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $128.27 | 2019-2024 | Rexulti |
| Lundbeck LLC | $115.65 | 2019-2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $58.97 | 2023 | |
| Vertical Pharmaceuticals, LLC | $38.26 | 2025 | Relexxii |
| Shire North American Group INC | $30.64 | 2019 | |
| Janssen Scientific Affairs, LLC | $29.32 | 2019 | |
| Vanda Pharmaceuticals INC. | $24.04 | 2025 | Fanapt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.84 | 2019 | |
| Alfasigma USA, INC. | $17.91 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.